官方服务：
资源简介：
Digenome-seq of Cas9 nuclease targeting HTT
应用场景：
创建时间：
2023-02-24
相关数据集
Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington’s Disease Models
Genetic and pharmacological evidence indicates that the reduction of ataxia telangiectasia-mutated (ATM) kinase activity can ameliorate mutant huntingtin (mHTT) toxicity in cellular and animal models
NIAID Data Ecosystem70
Additional file 10: of NmeCas9 is an intrinsically high-fidelity genome-editing platform
Table S3. Targeted deep sequencing read count data for all sgRNAs used and for all off-targets detected by GUIDE-seq. (XLSX 44 kb)
Figshare2024-02-08 更新60
Large Serine Integrase Off-target Discovery and Validation for Therapeutic Genome Editing
While numerous technologies for the characterization of potential off-target editing by CRISPR/Cas9 have been described, the development of new technologies and analytical methods for off-target recom
NIAID Data Ecosystem20
Additional file 1 of HD_BPMDS: a curated binary pattern multitarget dataset of Huntington’s disease–targeting agents
Additional file 1. HDACs-specific fingerprint.
Figshare2024-08-14 更新60
North America Huntingtons Disease Therapeutics Market
The North America Huntingtons Disease Therapeutics report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth tr
IMR REPORTS50
